The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biofrontera's Revenue for the
three
months ended in Dec. 2023 was $10.60 Mil. Biofrontera's average Accounts Receivable for the
three
months ended in Dec. 2023 was $4.48 Mil.
Hence, Biofrontera's Receivables Turnover for the
three
months ended in Dec. 2023 was 2.37.
Biofrontera Receivables Turnover Historical Data
The historical data trend for Biofrontera's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biofrontera's Receivables Turnover
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera's Receivables Turnover Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biofrontera's Receivables Turnover falls into.
Biofrontera Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Biofrontera's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biofrontera Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Biofrontera's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BFRI has been successfully added to your 